Preventing Bone Loss After Breast Cancer Treatment Using Osteoporosis Drug
Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented
Original post by Women’s Health / Gynecology News From Medical News Today
Related Articles
Early Results Show Promise In Reducing Side Effects From Anastrozole, UK FDA Panel OKs Osteoporosis Drug To Cut Breast Cancer Risk FDA Panel Recommends Osteoporosis Drug Evista For Breast Cancer Prevention Forteo Increases Bone Density In Steroid-Induced Osteoporosis Brittle Bones Drug And Breast Cancer
